CN Mobile Logo


Oncology and Hematology News and Journal Articles

New ACS Guidelines for Breast Cancer Screening

New breast cancer screening guidelines from the American Cancer Society recommend pushing the start of screening back by 5 years and screening every other year rather than annually starting at age 55.

Recent Content

Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.

Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.

The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.

A case study of a 15-year-old CML patient suggests that a reduced intensity conditioning regimen following hematopoietic stem cell transplantation could be a good treatment option for young CML patients. The patient went on to have two pregnancies with no neonatal complications.

A retrospective cohort study showed that socioeconomic variables including race, marital status, insurance status, and geography are associated with rates of resection for early-stage pancreatic cancer. Most of these factors, however, were not associated with survival following resection.

A combination of cobimetinib and vemurafenib prolongs overall survival in melanoma patients with BRAF V600 mutations.

The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.

By clicking Accept, you agree to become a member of the UBM Medica Community.